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ABSTRACT 
Saeid Malboubi, DDS 
Boston University, Goldman School of Dental Medicine, 2009 
Major Professor: 
Alpdogan Kantarci 
Assistant Professor of Periodontology and Oral Biology 
Platelet-rich plasma (PRP) is a concentrated gel of platelets that contains several growth 
factors. Growth factors have been recognized as the part of PRP that play role in regeneration of 
the bone. It is not clear how these growth factors in PRP affect the bone regeneration. Resolvin 
El (RvEl; 5S,12R,18R-trihydroxyeicosapentaenoic acid) is an pro-resolving lipid mediator 
derived from omega-3 fatty acid eicosapentaenoic acid and shown to have potent effects on the 
resolution of inflammation. The purpose of this study was to analyze the action of PRP and 
RVEl on the proliferation and behavior of osteoblasts and osteoclasts in vitro. PRP was 
prepared from 14 healthy donors. Osteoblast cultures were from a cell line (Saos2) of 
osteosarcoma cells. Osteoclasts were differentiated from primary human peripheral blood 
monocytes. Osteoclastic morphology was studied and activity was analyzed via resorption on 
dentin discs using SEM. PRP and RVE 1 were added at different doses and time-points. 
Osteoblast function was analyzed by osteocalcin expression and release. Osteoclast activity was 
assessed by resorption and cathepsin K expression. PRP and RvEl comparably increased the 
11 
osteoblastic activity and suppressed the osteoclast differentiation and function. These results 
suggest that multiple tools are available to reverse the inflammation and restore the lost bone 
architecture as a result of periodontal disease. 
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I. INTRODUCTION 
Regeneration and restoration of hard tissues in the periodontium present the major 
challenge in periodontal therapy. Various mechanical techniques have been used with limited 
success. A true regeneration can only be accomplished through the modification of biological 
mechanisms of tissue turnover in order to favor the formation over destruction. Clinical 
application ofbioactive molecules in periodontal regeneration is not a new approach; however, 
recent developments in understanding the processes of how the bone turnover is regulated and 
thus could be modified through the growth factors and various other bioactive molecules have 
introduced novel tools for the regeneration of the lost tissues due to the inflammatory processes 
in periodontium. 
Platelet rich plasma is a relatively new technique through which various growth factors 
from the patient's own blood can be prepared and used during the surgical procedures in the oral 
cavity. To date, at least seven growth factors have been identified in platelet rich plasma and 
these factors have been attributed to various biological aspects of the wound healing. While the 
efficacy of the platelet rich plasma around periodontal defects is a controversial issue in clinical 
trials, periimplant and bone augmentation applications have been shown to enhance the success 
of bone grafting. On the other hand, it is still not clear how the bone regeneration could be 
enhanced through the introduction of concentrated growth factors in platelet rich plasma. 
It has been suggested that the clinical inflammation could be one of the major limiting 
factors in the success of the delivery of growth factors and their functional properties. Recent in 
vitro and in vivo data from our group have demonstrated that the inflammation in periodontal 
tissues could be reversed and resolution of inflammatory events would result in complete 
regeneration of the periodontal tissues lost due to periodontal infection. These encouraging 
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results have been obtained using various novel compounds, which are collectively known as 
resolution agonists. Resolvin E 1 is the most well characterized member of this genus of 
resolution phase mediators of inflammation. 
In this study, we have tested the functional impact of platelet rich plasma and Resolvin 
E 1 on the osteoblasts and osteoclasts in vitro. The results show that these two distinct biological 
strategies suppress the osteoclastic activity and enhance the osteoblastic function. These 
findings imply that the combination of these techniques can overcome the shortcomings of the 
clinical success of platelet rich plasma as a potential treatment method to accomplish periodontal 
regeneration. 
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II. BACKGROUND 
A. Alveolar Bone 
1. Structural and Functional Characteristics of the Alveolar Bone 
The alveolar bone is the thickened ridge of the mammalian jaw, which contains the dental 
alveoli. It is also referred to as the alveolar process. In humans, the tooth-bearing bones are the 
maxilla and the mandible [1]. Dental alveoli are the sockets in the jaws in which the roots of the 
teeth are held in the alveolar process of maxilla with the periodontal ligament. Alveolar bone 
provides the primary support to teeth. Comparable to other parts of the skeleton, alveolar bone 
undergoes a continuous and rapid remodeling during tooth eruption and mastication. 
The anatomy of the alveolar bone is complex [2]. Alveolar bone is composed of bundle 
bone [3], which is formed in lamellae parallel to the coronal-apical direction of the tooth. 
Sharpey's fibers extend obliquely from the lamellae and are continuous with fibers of the 
periodontal ligament. Outer layer of the alveolar bone forms the lingual and labial surfaces of 
the alveolar process. This layer is a thick cortical plate extending from the jaws. There are 
numerous marrow spaces within the cancellous bone and smaller endosteal spaces present in the 
cortical bone. Some of the small endosteal spaces extend into the periodontal ligament [ 4]. 
The ability of bone cells derived from adult rabbit alveolar bone to form mineralized 
tissue nodules, which looks like the bone, has been described [5]. While these studies and 
different systems provide some investigating specialized aspects of the molecular and cellular 
biology of alveolar bone in a controlled environment, but still most of the current information 
about alveolar bone comes from studies of other bone tissues in the skeleton. [ 6] 
The alveolar bone forms in relation to the teeth [7] but structurally it is similar to, and 
continuous with, the basal bone. Paracrine factors, including cytokines, chemokines and growth 
3 
factors, which have been implicated in the local control of mesenchymal condensations that 
occur at the onset of organogenesis, are likely to have a prominent role in the development of the 
alveolar processes. While the growth and development of the jaw determines the position of the 
teeth, a certain degree of re-positioning of teeth can be accomplished through occlusal forces and 
in response to orthodontic procedures that rely on the adaptability of the alveolar bone and 
associated periodontal tissues. 
2. Cells of the Alveolar Bone 
Osteoblasts 
Osteoblast is a mononucleated cell that is responsible for bone formation. Osteoblasts 
produce the osteoid, which is composed mainly of Type I collagen. Osteoblasts are also 
responsible for mineralization of the osteoid matrix. In the course of development during 
embryonic steps, osteoblasts arising from condensing mesenchyme in the facial region, forms 
intramembranous bone of the maxilla and mandible initially which later creates bony alveoli that 
house all the teeth of the developing dentition. 
Osteoblasts are the most active secretory cell in bone. They are generally cuboidal or 
slightly elongated cells that cover a large percentage (depending on age and anatomical site) of 
bone surfaces. Osteoblasts are responsible for the production of the organic matrix of bone [8]. 
Osteoblasts form an extensively perforated sheet with other adjacent osteoblasts, which, in 
addition to producing alveolar bone matrix proper, must additionally embed continuously 
remodeling periodontal ligament fibers in a rather precise manner [9] 
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Continuous bone remodeling at the innermost layer alveolar surface (socket) and within 
the alveolar bone causes temporary detachment of small portions of the periodontal ligament 
from the alveolus. This process is rapidly followed by synthesis of new periodontal ligament by 
fibroblasts together and new alveolar bone production by osteoblasts. The repair process allows 
for re-attachment at the remodeled sites. Remodeling of the alveolar bone allows for 
maintenance of tooth biomechanical function. Since osteoblasts are of mesenchymal origin, 
when they are fully differentiated and actively secreting bone matrix, they become the post-
mitotic cells containing a cytoplasm rich in synthetic and secretory organelles such as rough 
endoplasmic reticulum, Golgi apparatus, secretory granules and microtubules [ 1 O]. 
The osteoblasts produce organic matrix that contains mostly type I collagen and various 
other noncollagenous bone proteins and plasma proteins [ 11]. The major collagen-producing 
cells are osteoblasts, fibroblasts and odontoblasts [12]. Studies on bone and teeth demonstrated 
phosphoprotein and/or glycoprotein deposition into prebone ( osteoid) and predentin, followed by 
its subsequent accumulation at the mineralization in these tissues [ 13]. Therefore, as shown for 
collagen, the release of noncollagenous proteins appears to occur primarily at the base of 
osteoblast (and odontoblast) cell processes and from the cell body itself. While some secreted 
proteins associate with the collagen to form new matrix, some of the acidic proteins appear to 
diffuse through the osteoid and, due to their affinity for hydroxyapatite, accumulate at the 
mineralization front. Collagen fibril formation in bone is initiated when collagen filaments 
released by osteoblasts assemble extracellularly into striated fibrils to form the osteoid, a light 
microscopic term for the seam of unmineralized bone matrix closest to the osteoblast, although 
numerous small foci of mineralization can also be observed within the osteoid layer by electron 
microscopy [14]. Certain noncollagenous and plasma proteins co-localize with these early foci, 
5 
although the vast majority appear to accumulate at the mineralization front and throughout the 
mineralized bone matrix [15]. 
Osteocytes 
The osteocyte is a star-shaped cell and the most abundant cell in compact bone. When 
osteoblasts become trapped in the matrix they secrete, they become osteocytes. Osteocytes are 
networked to each other via long cytoplasmic extensions that occupy tiny canals called 
canaliculi, which are used for exchange of nutrients and waste. The space that an osteocyte 
occupies is called a lacuna. Although osteocytes have reduced synthetic activity and, like 
osteoblasts are not capable of mitotic division, they are actively involved in the routine turnover 
of bony matrix, through various mechanosensory mechanisms. Similar to the osteoblasts, 
osteocytes develop in the mesenchyme. Hydroxyapatite, calcium carbonate and calcium 
phosphate are deposited around the osteocytes as they differentiate from osteoblasts. 
Osteocytes are one of the mature shapes of osteoblasts . After maturation, osteoblasts may 
undergo apoptosis, trapped in matrix as osteocytes or remain on the bone surface as bone lining 
cells. Ones that tum to be osteocytes occupy spaces (lacunae) in bone and are defined as cells 
surrounded by bone matrix , whether mineralized or still part of the osteoid seam [ 16]. 
Osteocytes have a decreased quantity of synthetic and secretory organelles, and are smaller cells 
than osteoblasts with the nucleus occupying a significantly larger proportion of the cell. 
Although they are diminished in size, these cells have the full complement of organelles capable 
of effecting protein secretion [17], a feature perhaps reflected by the variable appearance of the 
perilacunar matrix frequently observed surrounding these cells [18]. 
A major feature of osteocytes is the presence of numerous and extensive cell processes 
that ramify throughout the bone in canaliculi and make contact, frequently via gap junctions, 
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with processes from other osteocytes or with similar processes extending from osteoblasts or 
bone-lining cells at the surface of the bone [19]. Thus, considerable potential exists for 
communication among these cells, a factor of great importance considering the spatial isolation 
of osteocytes within such a dense, rigid mineralized matrix. 
Bone-lining Cells 
Bone-lining cells cover most bone surfaces in the adult skeleton [20]. These flat cells that 
line non-remodeling endosteal bone surfaces are suggested to be a distinct phenotype with 
distinct morphology and important functional roles in skeletal physiology, metabolism, and 
remodeling. The transition from osteoblast to bone-lining cell clearly involves a series of 
gradual morphological and functional changes that culminate in decreased protein secretion [21]. 
The relative paucity of organelles in these cells indicate that they are less involved in secretion of 
bone matrix. Transformation of osteoblasts into bone-lining cells may represent the final 
phenotype of the osteoblast lineage prior to activation of the bone remodeling. The ultimate fate 
of bone-lining cells is presumably death by apoptosis . Although in mammals there is little 
evidence that bone-lining cells can regain a capacity to produce lamellar bone matrix, in adult 
birds, bone-lining cells appear to retain osteogenic potential, proliferating in response to estrogen 
and contributing to the formation of woven medullary bone [22]. Together with osteocytes, bone 
lining cells and their connecting cell processes appear to form an extensive homeostatic network 
of cells capable of regulating plasma calcium concentration through mechanisms partly 
independent of those related to the bone remodeling system [23]. 
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Osteoclasts 
An osteoclast (from the Greek words for "bone" and "broken") is a type of bone cell that 
removes the bone tissue by removing its mineralized matrix. This process is known as bone 
resorption. Osteoclasts and osteoblasts are instrumental in controlling the amount of bone tissue. 
Osteoclasts are formed by the fusion of cells of the monocyte-macrophage cell lineage. 
Osteoclasts are critical for bone to respond to biological regulatory factors and functional forces. 
The coupling of bone resorption with bone formation constitutes one of the fundamental 
principles by which bone is necessarily remodeled throughout life [24]. 
Apart from its multinucleation, the most striking feature of the osteoclast is the presence 
of an actin-, vinculin- and talin-containing clear (sealing) zone in the peripheral cytoplasm that 
delineates a more central region of membrane infoldings (plates) and finger-like processes 
termed the ruffled border [25]. Resorption of bone occurs in an acidified extracellular matrix 
compartment as a result of the combined actions of a variety of ruffled border membrane-
associated enzymes including a tartrate-resistant, vanadate-sensitive acid adenosine 
triphosphatase, carbonic anhydrase isozyme II and proton-pumping adenosine triphosphatases 
[26]. Although numerous states of osteoclast differentiation can be observed and are reflected by 
different osteoclast morphologies, it is thought that the presence of small and large cathepsin-
containing cytoplasmic vacuoles/vesicles, often in the immediate vicinity of the ruffled border, 
are indicative of resorptive activity by these cells. Among these membrane-bound structures, 
there exists a population of small, spherical vesicles having a single indentation of the membrane 
at one site and appear to contain lysosomal and plasma membrane enzymes, and thus may 
participate in certain degradative activities performed by the osteoclast and/or plasma membrane 
recycling [27]. 
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Once activated, osteoclasts move to areas of micro fracture in the bone by chemotaxis. 
Osteoclasts lie in a small cavity called Howship's lacunae, formed from the digestion of the 
underlying bone. The sealing zone is the attachment of the osteoclast plasmalemma to the 
underlying bone. Sealing zones are bounded by belts of specialized adhesion structures called 
podosomes. The osteoclast releases hydrogen ions through the ruffled border into the cavity, 
acidifying and dissolving the mineralized bone matrix. In addition, several hydrolytic enzymes, 
such as members of the cathepsin ( e.g. Cathepsin K) and matrix metalloproteinase (MMP) 
groups are released to digest the organic components of the matrix. 
Osteoclast formation requires the presence of RANK ligand or RANK-L (receptor 
activator of nuclear factor K~) and M-CSF (Macrophage colony stimulating factor). These 
membrane bound proteins are produced by neighboring stromal cells and osteoblasts . 
M-CSF acts through its receptor on the osteoclast, c-fms (colony stimulating factor 1 receptor), a 
transmembrane tyrosine kinase receptor, leading to activation of tyrosine kinase Src. Both of 
these molecules are necessary for osteoclastogenesis and are widely involved in the 
differentiation of monocyte/macrophage-derived cells. RANKL is a member of the tumour 
necrosis family (TNF), and is essential in osteoclastogenesis. RANKL activates NF-K~ (nuclear 
factor-K~) and NFATcl (nuclear factor of activated t cells , cytoplasmic, calcineurin-dependent 1) 
through RANK. Osteoclast differentiation is inhibited by osteoprotegrin (OPG), which binds to 
RANKL thereby preventing interaction with RANK [26]. Osteoclast function is regulated by 
several hormones, including parathyroid hormone (PTH) from the parathyroid gland, calcitonin 
from the thyroid gland, and IL-6 [26]. 
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3. Extracellular Matrix of the Alveolar Bone 
The composition of the extracellular matrix of alveolar bone appears to be similar to 
other bone tissues as indicated largely by immunohistochemical analyses. The bone matrix is 
formed from a scaffold of interwoven collagen fibers within and between which small, uniform, 
plate-like crystals of carbonated hydroxyapatite are deposited. Other proteins, including 
proteoglycans, acidic glycosylated and non-glycosylated proteins associate with and regulate the 
formation of collagen fibrils and mineral crystals, or provide continuity between matrix 
components and between the matrix and cellular components. In addition, small amounts of 
carbohydrate and lipid contribute to the organic matrix, which comprises approximately one-
third of the matrix while the inorganic components account for the remaining two-thirds. 
Calcium and phosphate in the form of poorly crystalline, carbonated apatite, predominates the 
inorganic phase, largely replacing the water component of the soft, dense connective tissues that 
include the periodontal ligament and gingiva. 
Collagen is the major protein associated with the bone matrix. Type I collagen is the 
principal collagen in mineralized bone together with type V collagen forming heterotypic fiber 
bundles that provide the basic structural integrity of connective tissues[28] [29, Lukinmaa, 1992 
#87]. In addition to these two forms, type III collagen in Sharpey' s. The expression of type XII 
collagen is related to mechanical strain and the alignment of collagen fibers, as demonstrated in 
the maturation of the periodontal ligament [30]. While the type I, V and XII collagen are 
expressed by osteoblasts, type III and type XII collagen fibers appear to be produced by 
fibroblasts during the formation of the periodontal ligament. 
The collagen fibrils in bone are stabilized by intermolecular cross-linking involving 
lysines and modified lysines that form pyridinium ring structures (pyridinolines). These cross-
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links are primarily responsible for the high tensile strength of collagen fibers, which are formed 
from fibrils as higher order structures laid down in a specific orientation by the bone-forming 
osteoblasts. In rapidly forming bone that is produced during early development and in repair 
sites, the fibers are extensively interwoven, leaving a substantial volume of interfibrillar space 
that is largely occupied by mineral crystals and associated acidic proteins. In mature (lamellar) 
bone, the collagen fibers form highly organized sheets in which successive layers of fibers are 
oriented perpendicular to each other with little interfibrillar space. In both woven and lamellar 
bone, the mineral crystals within the collagen fibrils are believed to form initially within the gap 
region between successive collagen molecules such that their axes are aligned with the long axis 
of the collagen fibril [31]. 
Other than collagen, there are several different other proteins are in the bone matrix. 
Some of these proteins, typically osteocalcin and bone sialoprotein, are essentially unique to 
mineralized tissues, whereas others, such as osteonectin/ SP ARC ( secreted protein, acidic, rich in 
cysteine) and osteopontin have a more general distribution. These proteins are released from 
bone by demineralization, reflecting the predominant association with the mineral phase. Other 
proteins are present in bone in specifically modified forms. Thus , small proteoglycans, primarily 
chondroitin sulfate proteoglycans, are present in bone whereas their dermatan sulfate 
counterparts are characteristically found in soft connective tissues [32]. The regulation of 
osteocalcin by osteotropic hormones, such as 1,25- dihydroxyvitamin D3 (vitamin D3) and 
parathyroid hormone, together with the ability of a carboxy- terminal segment to act as a 
chemoattractant to osteoclast precursors, also suggests a role in bone resorption [33]. Despite the 
structural similarities between osteopontin and bone sialoprotein, these proteins have clearly 
different functional roles. While bone sialoprotein is essentially restricted to mineralizing tissues, 
osteopontin has a more general distribution that reflects a broader biological role. Similar to 
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blood clotting factors, osteopontin is also susceptible to thrombin, indicative of an origin in the 
blood or blood-forming organs. Since bone sialoprotein is expressed coincident with the first 
appearance of mineral crystals in cementum and bone and is also able to nucleate hydroxyapatite 
crystal formation in vitro through the polyglutamate sequence, it is thought to function in the 
initiation of mineral crystal formation in vivo [34]. 
B. Remodeling of alveolar bone 
It has long been accepted that bone formation and bone resorption are processes that are 
"coupled". This coupling process entails that osteoclasts resorb an area of bone, and osteoblasts 
are signaled to come in and replace bone . The resorptive phase occurs over a 3- to 4- week 
period, whereas the formative phase occurs over a 3- to 4-month period. Between the resorptive 
and formation phases is a period termed the reversal phase. During the reversal phase, cells 
appear morphologically inactive [35]. Remodeling is a phenomenon that is happening in all 
bones. Complete remodeling of the alveolar bone however, occurs when the primary dentition is 
replaced by permanent teeth. The alveolar bone associated with the primary teeth is completely 
resorbed together with the roots while new alveolar bone is formed to support the newly erupted 
teeth. Significant remodeling of the alveolar process occurs as part of this process. The ability 
of the alveolar bone to remodel rapidly also facilitates positional adaptation of teeth in response 
to functional forces and in the physiological drift of teeth that occurs with the development of 
jaws [36]. Bone remodeling involves the co-ordination of activities of the osteoblasts and the 
osteoclasts . Regulation of bone remodeling is a complex process involving hormones and local 
factors acting in an autocrine and/or paracrine manner on the generation and activity of 
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differentiated bone cells. The associations between bone formation and remodeling and 
inflammatory response systems are further emphasized by the recent identification of' 'master 
genes'' involved in the generation of osteoblasts and osteoclasts that belong to families of 
transcription factors with prominent roles in the development of immune responses [36]. 
Bone formation involves the proliferation and differentiation of stromal stem cells along 
an osteogenic pathway that leads to the formation of osteoblasts. The process of cellular 
differentiation is controlled by a cascade of events that involves a combination of genetic 
programming and gene regulation by various hormones, cytokines and growth factors. While an 
understanding of the complexities of the differentiation process is still at an elementary stage, 
significant advances have been made in recent years in identifying regulatory genes and 
molecular markers that define specific stages of osteogenic cell development [3 7]. The alkaline 
phosphatase and collagen I expression are characteristic of the osteogenic lineage and their 
synthesis continues to increase while the expression of type II collagen is lost and type III 
progressively diminishes. At early stages of differentiation, the potential for entering alternate 
pathways of differentiation is retained, as depicted for periodontal cell differentiation [37, 38]. 
While stimulating bone resorption, it is essential for normal bone growth and 
mineralization and has a primary function in calcium absorption from the intestine. Vitamin D3 
strongly stimulates the synthesis of osteocalcin and osteopontin by osteoblastic cells while 
suppressing collagen production . Insulin and growth hormone have anabolic effects on bone . 
Insulin targets osteoblasts directly, stimulating bone matrix formation and mineralization, and 
indirectly affects bone formation through a stimulation of insulin-like growth factor-I produced 
in the liver [39]. 
Of the many growth and differentiation factors that influence bone formation, the bone 
morphogenetic proteins (BMP) have the most profound effect on bone formation. These 
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cytokines, which belong to the transforming growth factor (TGF) family, can induce 
chondrogenic and osteogenic differentiation in undifferentiated mesenchymal cells; their 
prolonged presence is required to generate endochondral bone in ectopic sites [ 40]. The insulin-
like growth factors (IGF I and II) are also potent anabolic agents in bone, having effects similar 
to transforming growth factor-b on matrix proteins and matrix metalloproteinases, but insulin-
like growth factors also stimulate proliferation of osteoblast precursors [ 40]. 
A variety of soluble and membrane bound factors play a critical role in regulating 
osteoclast formation, including growth factors, systemic hormones, and cells in the marrow 
microenvironment, such as osteoblasts and marrow stromal cells [ 41, 42]. Cell-to-cell 
interactions are important in both the formation and activity of the osteoclasts. Recent molecular 
biological studies have identified that transcription factors, such as c-Fos and PU.1 are required 
for osteoclast differentiation [ 41]. Typically, formation of osteoclasts involves fusion of 
monocytic precursors, which occur at the site of bone resorption. The hyaluronan receptor CD44 
is upregulated during this process and is required for fusion to take place. Together with CD44, 
the av~3 integrin is highly expressed in osteoclasts and osteoclast precursors; both receptors 
being a primary target for the bone matrix protein osteopontin in signaling, cell attachment and 
possibly for osteoclast chemotaxis (haptotaxis) and migration [ 43]. 
On the bone surface, osteoclasts become polarized and form a ruffled border beneath 
which bone resorption takes place. While the molecular mechanisms involved are not known, 
cell attachment and recruitment of Src appear to be crucial events, as evidenced by an 
osteopetrotic phenotype in Src knockout mice. Demineralization of the bone matrix, which is a 
prerequisite for matrix degradation, is achieved through the acidification of a protected 
environment beneath the ruffled border [ 43]. 
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Alveolar bone is dependent upon the presence of teeth for its preservation. Consequently, 
the alveolar bone ridge is progressively reduced following the extraction of teeth. 60% of the 
alveolar ridge width and 40% of its height can be lost (resorption) after 6 month after extraction 
[ 44]. Maintenance of alveolar bone is also compromised following trauma and inflammatory 
episodes associated with periodontal disease [ 45]. Preventing or minimizing the alveolar bone 
loss is a major clinical objective in dentistry, and restoration of alveolar bone mass after losses 
have been incurred is extremely difficult to attain. The interdependence of teeth and alveolar 
bone make the restoration of alveolar bone more difficult than simply enhancing osteogenesis 
[ 46]. Regeneration of bone lost through periodontal disease requires the simultaneous and 
coordinated regeneration of the associated periodontal tissues in an environment that is subject to 
ongoing inflammatory activity [ 47]. The ability of the alveolar bone to undergo rapid 
remodeling is of fundamental importance for physiological movement of teeth in the jaw that 
occurs in response to occlusive forces and orthodontic forces used for the clinical re-positioning 
of teeth [ 48]. At sites of alveolar bone compression, osteoclasts proliferate and an initial 
resorption of the superficial bone is believed to take place. The initial response may involve 
osteoblasts, which can produce collagenolytic enzymes to remove a portion of the unmineralized 
extracellular matrix, thereby facilitating access of osteoclast precursors to the bone surface. 
Osteoblastic cells also produce chemokines and cytokines, which can attract monocyte 
precursors and promote osteoclast differentiation and activity [ 49, 50]. 
15 
C. Regeneration of Alveolar Bone and Other Periodontal Structures 
Regenerative periodontal therapy aims to predictably restore the tooth's supporting 
periodontal tissues and should result in formation of a new connective tissue attachment (i.e. new 
cementum with inserting periodontal ligament fibers) and new alveolar bone. Histologic 
evidence from preclinical models has demonstrated periodontal regeneration following treatment 
with barrier membranes, various types of grafting materials or a combination. However, it is still 
not clear to what extent a combination of barrier membranes and grafting materials may 
additionally enhance the regeneration process compared with barrier membranes alone, grafting 
materials alone or open flap debridement [ 51]. 
Periodontal regeneration is defined histologically as regeneration of the tooth's 
supporting tissues, including alveolar bone, periodontal ligament, and cementum over a 
previously diseased root surface [52]. Regeneration takes place by growth from the same type of 
tissue that has been destroyed or from its precursor. In the periodontium, gingival epithelium is 
replaced by epithelium, and the underlying connective tissue and periodontal ligament are 
derived from connective tissue. Bone and cementum are not replaced by existing bone or 
cementum but by connective tissue, which is the precursor of both. Undifferentiated connective 
tissue cells develop into osteoblasts and cementoblasts, which form bone and cementum. 
Regeneration of the periodontium is a continuous physiologic process. Under normal conditions, 
new cells and tissues are constantly being formed to replace those that mature and die. This is 
termed wear and tear repair. It is manifested by mitotic activity in the epithelium of the gingiva 
and the connective tissue of the periodontal ligament, by the formation of new bone, and by the 
continuous deposition of cementum [53] 
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New attachment and osseous regeneration have been a constant but elusive goal of 
periodontal therapy since beginning of this century. Since the 1970s, renewed laboratory and 
clinical research efforts have resulted in new concepts and techniques that have moved us much 
closer to attaining this ideal result of therapy. Melcher pointed out that the regeneration of the 
periodontal ligament is the key to new attachment because it "provides continuity between the 
alveolar bone and the cementum and because it contains cells that can synthesize and remodel 
the three connective tissues of the alveolar part of the periodontium" [54, 55]. During the 
healing stages of a periodontal pocket, the area is invaded by cells from four different sources , 
oral epithelium, gingival connective tissue, bone, and periodontal ligament. The outcome of 
periodontal pocket healing depends on the sequence of events during the healing stages . If the 
epithelium proliferates along the tooth surface before the other tissues reach the area, the result 
will be a long junctional epithelium. If the cells from the gingival connective tissue are the first 
to populate the area, the result will be fibers parallel to the tooth surface and remodeling of the 
alveolar bone with no attachment to the cementum . If bone cells arrive first, root resorption and 
ankylosis may occur. Finally, only when cells from the periodontal ligament proliferate coronally 
is there new formation of cementum and periodontal ligament [54, 55]. 
Regenerative periodontal therapy comprises procedures which are specially designed to 
restore parts of the tooth supporting apparatus which have been lost due to periodontitis. A 
procedure must fulfill certain criteria to be considered a therapy, which encourages regeneration 
[ 56]. Conventional regenerative periodontal treatment can be non-graft-associated new 
attachment (like GTR) or graft-associated new attachment (GBR). Many techniques combine 
both approaches. Since the earliest attempts at periodontal new attachment, the presence of 
junctional and pocket epithelium has been perceived as a barrier to successful therapy because its 
presence interferes with the direct apposition of connective tissue and cementum, thus limiting 
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the height to which periodontal fibers can become inserted to the cementum. Several methods 
have been recommended to remove junctional and pocket epithelia [ 56]. Periodontal studies 
during the last several decades have led to new techniques and a new treatment approach referred 
to as guided tissue regeneration (GTR). This concept is based on the principle that specific cells 
contribute to the formation of specific tissues. Functions of bone graft materials include 
promoting osseous growth and bone healing, providing a structural substrate for these processes 
[57]. Bone graft materials can be used for osteogenesis, osteoinduction and osteoconduction. 
Osteogenesis occurs when living osteoblasts are part of the bone graft as in autogenous bone 
transplantation. Given an adequate blood supply and cellular viability, these transplanted 
osteoblasts form new centers of ossification within the graft. Hence, in addition to the bone 
formation from osteoblasts that already exists in the defect, osteoblasts that have been added as 
part of the bone graft also form ossification centers and contribute to the total capacity for bone 
formation [58]. Osteoinduction involves new bone formation via stimulation of osteoprogenitor 
cells from the defect ( or from the vasculature) to differentiate into osteoblasts and begin forming 
new bone. This induction of the bone-forming process by cells that would otherwise remain 
inactive occurs via cell mediators that "tum on" these bone forming cells. The most widely 
studied of these is the family of bone morphogenic proteins (BMPs) [59]. Osteoconduction is 
the formation of bone by osteoblasts from the margins of the defect on the bone graft material. 
Materials that are osteoconductive serve as a scaffold for bone growth. They do not inhibit bone 
formation, nor do they induce bone formation. They simply allow the normal formation of bone 
by osteoblasts into the grafted defect along the surface of the graft material. Osteoconductive 
bone graft materials facilitate bone formation by bridging the gap between the existing bone and 
a distant location that otherwise would not be occupied by bone [58]. 
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D. Growth Factors and Bone Regeneration 
Polypeptide growth and differentiation factors are a class of biological mediators, which 
have been shown to play a critical role in the stimulation and regulation of the wound healing 
process . Growth factors involved in repair and regeneration regulate several key cellular 
processes such as mitogenesis, chemotaxis, differentiation, and metabolism. The sequence of 
events necessary for periodontal regeneration relies on the above processes for osteogenesis, 
cementogenesis, and connective tissue formation. Numerous preclinical in vitro and in vivo 
studies have demonstrated that certain growth factors modulate putative components of 
periodontal wound healing resulting in substantial regeneration of the periodontium in animals 
[60]. 
Growth factors released by cells in the inflamed area that regulate events in wound 
healing . They can be considered hormones that are not released into the bloodstream but have 
only a local action. Growth substances regulate connective tissue cell migration, proliferation, 
and synthesis of proteins and other components of the extracellular matrix. These factors, 
primarily secreted by macrophages, endothelial cells, fibroblasts, and platelets, include platelet 
derived growth factor (PDGF), insulin-like growth factor (IGF), fibroblastic growth factor 
(FGF), and transforming growth factor (TGF). Growth factors could be used to control events 
during periodontal wound healing ( e.g., promoting proliferation of fibroblasts from the 
periodontal ligament and favoring bone formation). 
Periodontal regeneration is thought to require the migration and proliferation of 
periodontal ligament cells on the root surface. In fact, repopulation of the detached root surface 
by cells from periodontal ligament (PDL) is a prerequisite for new attachment formation. 
Studies analyzed the mitogenic effects determined on periodontal ligament cells by growth 
19 
factors using (3H) thymidine incorporation during DNA synthesis. The results suggested that 
recombinant human PDGF and IGF-I stimulate the proliferation of PDL fibroblastic cells and the 
combination of these growth factors showed a synergistic effect revealing the highest mitogenic 
effect among all individual growth factors as well as any combination of the growth factors 
tested. Furthermore, these studies demonstrated that rh-PDGF and IGF-I stimulate chemotaxis of 
PDL fibroblastic cells, and supported a role for TGF-~ as a regulator of the mitogenic response 
to PDGF in these cells. Other studies in vivo showed periodontal tissues regeneration introducing 
mixtures of recombinant human platelet derived growth factor and insulin-like growth factor into 
lesions of experimentally induced periodontitis in beagle dogs and monkeys [61]. Several 
growth factors and cytokines are effective on the synthesis of DNA, alkaline phosphatase, 
fibronectin, and secreted protein acidic and rich in cysteine in human periodontal ligament cells. 
E. Platelet Rich Plasma 
Platelets are small, irregularly shaped anuclear cells, 2-4µm in diameter, and are derived 
from fragmentation of precursor megakaryocytes. Each megakaryocyte produces between 5,000 
and 10,000 platelets. The average life span of a platelet is between 8 and 12 days. Platelets play 
a fundamental role in hemostasis and are a natural source of growth factor [62]. A normal 
platelet count in a healthy person is between 150,000 and 400,000 per mm 3 of blood. 
The platelet has numerous pseudopodia extensions, invaginations of its cell membrane, 
and internal vesicles (storage granules). The vesicles are composed of three types of granules: 
lysosomal, dense, and alpha. The lysosomal granules seem to function as storage for digestive 
enzymes. The dense granules mainly store and secrete adenosine diphosphate (ADP), which is a 
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potent recruiter and activator of other platelets. The alpha granules are the storage granules of the 
growth factors; they contain pre-packaged growth factors in an incomplete and therefore bio-
inactive form [63]. The growth factors contained in these granules are the three isomers of 
platelet-derived growth factor, which is a potent chemotactic agent (PDGFaa, PDGFbb, and 
PDGFab ), the two isomers of TGFP 1 and TGFP2, which stimulate the deposition of extracellular 
matrix. Other healing-associated growth factors produced by platelets include: FGF, IGF-1, 
VEGF, and EGF [64]. 
Local application of these factors in increased concentrations through PRP (platelet-rich 
plasma) has been used as an adjunct to wound healing for several decades [65, 66]; [67];[63]. 
The circulating platelet participates in natural wound healing based on its numbers in circulating 
blood. It further participates in enhanced wound healing by virtue of its increased concentration 
in PRP. In both situations, its secretion of growth factors is activated by the clotting process. The 
activation of the clotting process is associated with a structural change in the platelet membrane 
system and results in the active secretion of the growth factors from the alpha granules [68-71]. 
PRP is an otherwise normal autogenous blood clot that contains highly concentrated 
platelets. Because it is the patient's own blood, it is free of transmissible diseases and cannot 
cause hypersensitivity reactions. The minimum platelet count required for a blood clot to qualify 
as PRP may be arguable, but about 4 to 7 times the usual baseline platelet count has been shown 
to provide clinical benefits. A normal blood clot such as that found in a wound resulting from an 
implant drill site, a tooth socket, or a bone graft contains 94% red blood cells, 6% platelets, and 
some-what less than 1 % white blood cells. In contrast, a PRP blood clot contains 94% platelets, 
only 5% red blood cells, and 1 % white blood cells. This alteration of the cellular ratios in the 
wound blood clot, whereby cells that do not stimulate healing (red blood cells) are replaced by 
cells that stimulate all phases of healing (platelets), explains its ability to enhance healing. It also 
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underscores the simple strategy and benefit of PRP, which is to increase the growth factor 
actions on healing and bone regeneration by increasing the numbers of platelets [72-7 4]. 
The growth factors secreted by the platelets usually have two active sites and are 
therefore called dimers. They attach only to cells that have receptors to accommodate them. 
These receptors are on the surface membrane of the target cell. The growth factor never enters 
the target cell; instead, it activates the membrane receptor, which has an intracytoplasmic portion 
and therefore is often termed a transmembrane receptor. Two adjacent transmembrane receptors 
are then brought within a critical distance of each other to activate dormant intracytoplasmic 
signal transducer proteins. A signal transducer protein then detaches from the transmembrane 
receptor and floats in the cytoplasm toward the nucleus . In the nucleus, the transducer protein 
unlocks a specific gene sequence for a regulated cellular function, such as mitosis, collagen 
synthesis , osteoid production, etc. The significance of this process is that it explains why an 
exogenous application of growth factors, even in the highest concentration possible, cannot 
produce a sustained overreaction such as a hyperplasia, a benign tumor, or a malignant tumor. 
Growth factors are not mutagenic; they are natural proteins acting through normal gene 
regulation and normal wound-healing feedback control mechanisms [72]. The alpha granules 
contained in platelets , whether in a normal blood clot or in a PRP clot, begin degranulating 
within 10 minutes of clot development and secrete over 90% of their pre-packaged growth 
factors within 1 hour. The growth factors immediately bind to the transmembrane receptors of 
osteoprogenitor cells, endothelial cells, and mesenchymal stem cells. The fibrin and fibronectin 
contained within the acellular portion of the clot and the vitronectin arising from the platelet 
alpha granules envelop the graft in an initial matrix. 
The three isomers of PDGF act as mi to gens for osteoblast, endothelial cell, and 
mesenchymal stem cell proliferation. The two TGF isomers accomplish a similar mitogenesis 
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and angiogenesis but also promote osteoblastic differentiation of the mesenchymal stem cells. 
The VEGF promotes specific capillary growth. The EGF is likely to be nonfunctional due to the 
absence of epithelial cells. Because of its increased concentration of platelets, the PRP thus 
initiates a greater and faster initial cellular response in the bone graft than the normal blood clot. 
Identifiable osteoprogenitor cell mitosis and capillary buds can be seen as early as 3 days after 
graft placement. By 17 to 21 days, the capillary penetration of the graft is complete and the 
osteoprogenitor cells have vastly increased in number. Thus, the first phase of bone graft healing 
occurs during the first 3 weeks and is characterized by capillary growth and rapid cellular 
metabolism, proliferation, and activity. It is during this phase that the graft is most vulnerable to 
infection and instability, either of which can prevent, or lyse, the delicate cells and cellular func-
tions occurring during this time. The clinician who understands this will take measures to ensure 
that the tissue is infection- and contamination-free and will provide absolute graft stability during 
this period [75]; [76]. 
Platelets and PRP act in the early biochemical first phase of a three-phase bone-
regeneration sequence, when the pivotal role of setting the rate and amount of bone regeneration 
takes place [67];[77]. The seminal study validating the concentration of platelets and their 
stimulation of bone graft healing documented that PRP is a concentration of platelets 4 to 7 times 
above baseline peripheral blood platelet levels. The study further demonstrated that bone graft 
cells do indeed possess membrane receptors for nearly all of the growth factors contained within 
platelets [78]. In addition, radiographs and computerized tomography scans showed an increase 
in bone mineral density in PRP-supported grafts that ranged from 1.6 to 2.2 times that of non-
PRP-supported grafts. This increase indicated a clinically more rapid formation and earlier 
maturation of the bone grafts that were stimulated by the PRP. Histomorphometry showed that 
while autogenous bone grafts without PRP enhancement produced a trabecular bone value of 55 
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± 8% (compared to a native value of 38 ± 6%, the PRP-enhanced grafts produced a value of74 
± 11 % . A combination of PRP, bovine porous bone mineral (BPBM) and GTR has been shown 
to be effective in promoting clinical signs of periodontal regeneration in intrabony defects. The 
results of the study by Camargo suggest that PRP and BPBM provide an added regenerative 
effect to GTR in promoting the clinical resolution of intrabony defects on patients with severe 
periodontitis [79]. Autogenous bone with added PRP in treatment of intrabony defects caused by 
periodontitis has given significant clinical improvement of the periodontal tissues. The 
combination of PRP and autogenous bone caused the elimination of a convenient environment 
for subgingival bacterial plaque eliminating periodontitis [80]. 
Combinations of PRP/BPBM/GTR and PRP/BPBM are effective in the treatment of 
intrabony defects present in patients with advanced chronic periodontitis [81]. In a controlled 
clinical study to compare PRP combined with a biodegradable ceramic, porous hydroxyapatite 
(HA) with a mixture of HA and saline in the treatment of human intrabony defects, treatment 
with a combination of PRP and HA compared to HA with saline led to a significantly more 
favorable clinical improvement in intrabony periodontal defects [82]. In a study to evaluate the 
gingival fibroblast proliferative response derived from patients with chronic and aggressive 
periodontitis to homologous PRP, the addition of PRP to human gingival fibroblast cultures 
significantly increased the proliferative response, irrespective of the presence of periodontitis, 
type of periodontitis and PRP donor [83]. In a randomized, double-masked, clinical trial to 
compare platelet-rich plasma (PRP) combined with a demineralized freeze-dried bone allograft 
(DFDBA) to DFDBA mixed with a saline solution in the treatment of human intrabony defects, 
treatment with a combination of PRP and DFDBA led to a significantly greater clinical 
improvement in intrabony periodontal defects compared to DFDBA with saline. No statistically 
significant differences were observed in the hard tissue response between the two treatment 
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groups, which confirmed that PRP had no effect on hard tissue fill or gain in new hard tissue 
formation [84]. 
Autologous PRP used in an intentional replantation procedure for a periodontally 
involved lower right central incisor with 18 months follow-up demonstrated new bone formation 
around the apical portion of the root and all clinical parameters indicated a trend of healing. The 
mobility of this previously grade III mobile incisor returned to normal limits. It was speculated 
that intentional replantation with PRP application may induce wound healing and may induce 
bone formation [85]. 
F. Resolution of Inflammation and Regeneration 
Inflammation is the complex biological response of tissues to harmful stimuli [86]. It is a 
protective attempt by the organism to remove the injurious stimuli as well as initiate the healing 
process for the tissue . Acute inflammation is a short-term process, usually appearing in a few 
minutes or hours and ceasing once the injurious stimulus has been removed [87]. Many 
mediators are released from "effector cells". The role of IL-12, IL-5, IL-4 and some adhesive 
molecules is presented with special attention focused on therapeutical aspects in allergic diseases 
[88]. The process of acute inflammation is initiated by cells already present in all tissues, mainly 
resident macrophages. Vasodilation and its resulting increased blood flow cause the redness 
(rubor) and increased heat (calor) . Increased permeability of the blood vessels results in an 
exudation (leakage) of plasma proteins and fluid into the tissue ( edema), manifesting as swelling 
(tumor). Some of the released mediators increase the sensitivity to pain (hyperalgesia, dolor). 
The acute inflammatory response requires constant stimulation to be sustained. Inflammatory 
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mediators have short half-lives and are quickly degraded in the tissue. Hence , inflammation 
ceases once the stimulus has been removed . 
The inflammatory response must be actively terminated when no longer needed to 
prevent unnecessary "bystander" damage to tissues [87]. Failure to do so results in chronic 
inflammation, cellular destruction, and attempts to heal the inflamed tissue. One intrinsic 
mechanism employed to terminate inflammation is the short half-life of inflammatory mediators 
in vivo. They have a limited time frame to affect their target before breaking down into non-
functional components, therefore constant inflammatory stimulation is needed to propagate their 
effects[89, 90]. 
Acute inflammation normally resolves by mechanisms that have remained somewhat 
elusive. Emerging evidence now suggests that an active, coordinated program of resolution 
initiates in the first few hours after an inflammatory response begins. After entering tissues, 
granulocytes promote the switch of arachidonic acid-derived prostaglandins and leukotrienes to 
lipoxins, which initiate the termination sequence. Neutrophil recruitment thus ceases and 
programmed death by apoptosis is engaged. These events coincide with the biosynthesis, from 
omega-3 polyunsaturated fatty acids, of resolvins and protectins, which critically shorten the 
period of neutrophil infiltration by initiating apoptosis. Consequently, apoptotic neutrophils 
undergo phagocytosis by macrophages, leading to neutrophil clearance and release of anti-
inflammatory and reparative cytokines such as transforming growth factor-B 1. The anti-
inflammatory program ends with the departure of macrophages through the lymphatics. [91] 
Bone is a highly dynamic organ that interacts with a wide array of cells and tissues. 
Recent studies have unveiled unanticipated connections between the immune and skeletal 
systems, and this relationship led to the development of a new field called osteoimmunology. 
This field will enable investigators to translate basic science findings in bone biology to clinical 
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applications for inflammatory diseases [92]. Inflammatory periodontal diseases constitute one of 
the most common infections in humans, resulting in the destruction of the supporting structures 
of the dentition. Circulating neutrophils are an essential component of the human innate immune 
system. The discovery of endogenous molecules involved in counterregulation of inflammatory 
responses that may lead to tissue injury provides an opportunity to explore new therapeutic 
approaches based on manipulation of new pathways. Natural counterregulatory pathways may 
reduce the possibility of unwanted toxic side effects [93]. 
During resolution, specific omega-3 polyunsaturated fatty-acid-derived mediators are 
generated within resolving exudates, including Resolvin El (RvEl) [94, 95]. The resolvins are 
distinctive and highly stereospecific lipids, which are endogenous local mediators with strong 
anti-inflammatory effects in addition to some immunoregulatory activities at picomolar to 
nanomolar concentrations. They are part of the molecular mechanisms that contribute to removal 
of inflammatory cells and restoration of tissue integrity once the need for the inflammatory 
response is over, i.e. they actively assist in the resolution of inflammation, once thought to be a 
passive process. It is evident that the presence of aspirin uniquely facilitates this resolution. 
Thus, at local sites of inflammation, aspirin treatment enhances the conversion of the omega-3 
fatty acids EPA and DHA to 18R-oxygenated products, i.e. resolvins of the E and D series, 
which carry potent anti-inflammatory signals [95]. 
In an in vivo study, RvEl has been found to be a potent proresolving mediator of 
inflammation derived from omega-3 eicosapentaenoic acid that acts locally to stop leukocyte 
recruitment and promote resolution. RvEl displays potent counter-regulatory and tissue-
protective actions in vitro and in vivo. Periodontal disease is a local inflammatory disease 
initiated by bacteria characterized by neutrophil-mediated tissue injury followed by development 
of a chronic immune lesion. In this study, the treatment of established periodontitis using RvEl 
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as a monotherapy in rabbits compared with structurally related lipids PGE2 and leukotriene B4. 
Promotion of resolution of inflammation as a therapeutic target with RvEl resulted in complete 
restoration of the local lesion, and reduction in the systemic inflammatory markers C-reactive 
protein and IL-1 p. This study shows that resolution of inflammation by a naturally occurring 
endogenous lipid mediator results in complete regeneration of pathologically lost tissues, 
including bone [96]. 
Topical application ofRvEl in rabbit periodontitis conferred dramatic protection against 
inflammation induced tissue and bone loss associated with periodontitis [97]. RvEl promotes 
phagocyte removal during acute inflammation by regulating leukocyte infiltration, increasing 
macrophage ingestion of apoptotic polymorphonuclear neutrophils in vivo and in vitro, and 
enhancing the appearance of phagocytes carrying engulfed zymosan in lymph nodes and spleen 
[94]. In a recent study, RvEl was shown to inhibit the osteoclast growth and bone resorption by 
interfering with osteoclast differentiation [98]. 
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III. HYPOTHESIS AND AIM 
The hypothesis in this study is that PRP enhances the osteoblast activity through the 
release of the growth factors and RvEl inhibits the osteoclast function. Since PRP has been 
shown to contain substantial amounts of lipoxin A4 [64], osteoclast activity may also be 
impacted by PRP's anti-inflammatory properties. Likewise, it is not known ifRvEl stimulates 
the osteoblast function. Therefore, these two distinct bioactive compounds could enhance the 
regenerative properties of the alveolar bone and their combination would explain the results 
shown by Hasturk et al. (2007) in vivo.[96] 
The aim of this study was to test the impact of PRP and RvEl on osteoblast and 
osteoclast function in vitro. Primary osteoclasts were differentiated from primary human 
peripheral blood monocytes while an osteoblast cell line was used to analyze the study outcomes. 
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IV. MATERIALS AND METHODS 
A. Preparation of PRP 
The study protocol has been approved by the Institutional Review Board of Boston 
University Medical Center. All subjects included in this study were medically and periodontally 
healthy volunteers recruited from the Clinical Research Center at Goldman School of Dental 
Medicine at Boston University. Informed consent was obtained. Smokers and individuals with 
systemic disease or history of anticoagulant, immunosuppressive, or antibiotic therapy in the last 
6 months were excluded. After reviewing the medical and dental histories, a detailed oral 
examination was performed. Individuals with a history or evidence of periodontal disease were 
not included. Thirty milliliters of blood was collected by venipuncture of the antecubital vein 
into two vacutainer tubes with acid citrate dextrose prepared. 
Platelet rich plasma was prepared based on the protocol previously described in our 
laboratory [64]. Briefly, blood samples were centrifuged at 500g for 10 minutes at room 
temperature. The top layer, which was the plasma fraction and the huffy coat layer were 
collected with sterile pipettes without contamination with red blood cells. These samples were 
further centrifuged at 700g for 15 minutes . The platelets were then pelleted and used as PRP. 
The upper layer, which was the clear and cell-free plasma, was transferred to another tube and 
saved as the platelet-poor plasma (PPP). The samples were then diluted in 1 % ammonium 
oxalate to hemolyze mature and possibly contaminating erythrocytes. A double Neubauer 
hemocytometer was used for platelet count determination. The PRP preparations were treated 
with 10% calcium chloride and bovine thrombin (low specific activity) mixture to activate the 
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platelets. The samples were coagulated within a few seconds of activation and centrifuged at 
5,000g for 10 minutes. The supernatant was collected and frozen at -70C to be used in cultures. 
B. Osteoblast Culture 
Saos-2 cell line was used for the osteoblast culture experiments. This cell line is derived 
from human osteosarcoma and purchased from ATCC. The cell culture was performed 
according to the manufacturer's protocol. McCoy's 5A (Invitrogen) was used as the culture 
medium. The medium was supplemented by 15% fetal bovine serum (FBS; ATCC) and 1 % 
penicillin/streptomycin to prevent any possible contamination. Cells were shipped in vials 
containing 5% DMSO and thawed for 2 minutes in a warm water bath at 3 7°C. The vials were 
then transferred to a 15 ml-tube and washed with lx PBS or media in 700-1000 rpm for 10 
minutes to eliminate the DMSO and other preservatives. The supematants were discarded and 
media was added. Cells were resuspended gently, counted by hemocytometer; and 1.6 - 2 
million cells were transferred to two 25ml dishes. The viability was checked under a light 
microscope. All containers were kept at 37°C. Cells were inspected every day to observe the 
confluency. After cells became confluent, they were split and passaged in 75ml flasks by 
trypsinizing using trypsin/EDT A (1 ml trypsin/EDTA for a 25 cc dish). Standard and uncoated 
6-well plates were used for osteoblast experiments. Each well contained 500,000 cells and 
treated with different assay conditions as outlined below. 
C. Primary Osteoclast Differentiation 
Primary osteoclasts were differentiated from peripheral blood mononuclear cells obtained 
from healthy donors. After isolation by Ficoll-Hypaque density gradient centrifugation, the top 
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monocyte-rich layer was used in these experiments. This method reproducibly yielded active 
osteoclasts in 13-17 days. 
After isolation, the monocytes were centrifuged at 1000 rpm for 10 minutes; the 
supernatant was discarded and the cell pellet was resuspended in warm media of MEM 
supplemented with 10% FBS and 1 % penicillin/streptomycin. The cells were cultured for 2 
hours at 37°C. Non-adherent cells (mainly lymphocytes) were washed with warm media and 
adherent monocytes were used to generate osteoclasts. For 24 hours, the cells were kept in 
MEM supplemented with 10% FBS and 1 % penicillin/streptomycin. 
In order to generate the osteoclasts, monocyte cultures were supplemented with M-CSF 
(10 µg lyophilized powder), RANKL (10 µg lyophilized powder), and TGF-~1 (2 µg lyophilized 
powder). The stock concentration of these molecules was 1000 ng/ml (M-CSF), 1000 ng/ml 
(RANKL), and l00ng/ml (TGF-~ 1). The final concentration in the media was adjusted to 25, 
50, and 5 ng/ml for M-CSF, RANKL, and TGF-~l, respectively. The media was changed every 
other day and supplemented with these molecules for 13-1 7 days. 
The osteoclast phenotype and function were confirmed at multiple levels. These 
measures were also used as study outcomes to test the impact of PRP or RvEl on osteoclast 
function. The first identification method was the morphological characterization. Detection of 
giant, multinucleated cells was used as the phenotypic differentiation for monocyte-derived 
osteoc lasts. 
The second level of analysis was made at functional level. The dentin pit assay was used 
to determine the osteoclastic resorption. Commercially available dentin discs were purchased 
from ATCC and their upper side was marked using a pencil. The discs were placed in 24-well 
plates and monocyte differentiation into osteoclasts was performed on these discs. In order to 
ensure that the disc orientation does not change during the culture, the discs were pre-wetted 
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with media before the cell culture fluid were added. After they morphological identification of 
the multinucleated giant osteoclast-like cells, the dentin discs were removed and placed in a new 
24-well plate. The discs were washed with ammonium hydroxide for 10 minutes followed by 
PBS to remove all the remaining cells and the debris. The discs were dried for 24 hours in room 
temperature and resorption patterns were analyzed by electron microscopy. Scanning electron 
microscopy (SEM) was used to measure the extent and depth of pit resorption. The discs were 
covered with gold foil and analyzed. The picture of each pit was captured and stored for 
analysis. Olympus software was used to measure the area and the number of pits per sample. 
D. Assay Conditions and Study Design 
For osteoblast experiments, dose-dependent actions of PRP was tested. RvEl was tested 
only at 1 dose (3 ng/ml) comparable to the in vivo studies. Medium-only culture with or without 
the addition of FBS served as the negative control. PRP was tested at 5%, 10%, and 20% 
concentrations (v/v). Time-dependent changes were assessed at 24, 48, 72, and 96 hours of 
culture . 
For osteoclast experiments, negative control was the medium without any FBS and 
medium with FBS served as the positive control since the end-point in these experiments were 
the inhibition of osteoclast differentiation and function. PRP was tested at 5, 10, and 20% 
concentrations. RvEl was tested at 3 ng/ml. 
E. Osteocalcin Expression and Release by Osteoblasts 
Osteoblast function was analyzed by the osteocalcin expression and release into the 
supematants. The expression analysis was based on the mRNA detection of osteocalcin in 
osteoblast lysates using the quantitative real-time PCR (Q-PCR). 
33 
mRNA extraction and preparation were done by using the conventional methods. 
Briefly, the cells were lysed in the RLT buffer. RNAse-free water and 15 cc tubes were used. 
All procedures were performed on ice to prevent the denaturation of the RNA and all the 
instruments, hands, and benches were RNA- free. mRNA was extracted using the protocols by 
the manufacturer (Qiagen). Extracted mRNA measured for quantity and quality (purity) with 
Nanodrop. Two micrograms ofmRNA of each sample was reverse transcribed to cDNA using 
the kit from Applied Biosystems. To confirm the presence of target genes in the PCR product, 
gel electrophoresis was run using a 1 Kb ladder. Actin was used as the internal control for 
loading and quantifying the expression response of osteocalcin and cathepsin K (for osteoclasts). 
The oligonucleotide primer sets used for human osteocalcin were 5'-
ACACTCCTCGCCCTATTG-3' (forward) and 5'-GATGTGGTCAGCCAACTC-3' (reverse) . 
These were ordered from Invitrogen. 
Osteocalcin release in the culture fluid was measured by a commercially available ELISA 
kit from ALPCO. 
F. Cathepsin K Expression in Osteoclasts 
Since cathepsin K expression is a marker for osteoclast activity and function, cathepsin K 
in osteoclasts with or without treatment with PRP or RvEl was measured with Q-PCR. 
Cathepsin K primers for measuring gene expression in osteoclasts were 5 ' -
AAGAAGAAAACTGGCAAACT-3' (5' forward), 5'-ATCGTTACACTGCACCATCG-3' (3' 
reverse). They were ordered from Invitrogen. 
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V.RESULTS 
A. Osteocalcin Expression in Osteoblasts 
In order to investigate the impact of PRP and RvEl on osteoblast function, first we 
studied the gene expression of osteocalcin in osteoblasts. For these experiments, we have used a 
single concentration of PRP at 10% (v/v) and a single concentration ofRvEl (3ng/ml). The 
negative control was used for normalization of the fold change after all values were standardized 
against the actin control. Q-PCR was used to measure the mRNA levels of osteocalcin 
expression. The results shown in Figure 1 demonstrates that PRP leads to an increase in 
osteocalcin mRNA expression after 72 hours and this effect stays constant over 96 hours both of 
which time-points are statistically significant (p<0.05; ANOV A with Bonferroni correction for 
multiple comparisons) compared to the positive control. Likewise, RvEl treatment leads to a 
significant increase in osteocalcin expression in osteoblasts at 72 and 96 hours over positive 
control (p<0.05; ANOV A with Bonferroni correction for multiple comparisons). 
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Figure 1. Osteocalcin mRNA expression in osteoblasts treated with PRP or RvEl. *p<0.05; 
ANOV A with Bonferroni correction for multiple comparisons. 
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B. Osteocalcin Release by Osteoblasts 
In order to analyze if the expression of osteocalcin is correlated with the functional 
release of osteocalcin by the osteoblasts in culture supematants, ELISA was used to measure the 
levels of osteocalcin. Figure 2 demonstrates that the released osteocalcin was significantly 
higher when the osteoblasts were treated with PRP or RvEl as early as 24 hours compared to the 
positive control. This effect continued for the 72 hours period while by the 96 hours, there is no 
significant production of osteocalcin in the culture medium. 
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Figure 2. Osteocalcin producti on by the osteoblasts treated with PRP or RvEl. *p<0.05 ; 
ANOV A with Bonferroni correction for multiple comparisons. 
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C. Osteoclast Count and Activity 
In order to check the impact of PRP or RvEl on the catabolism of the bone turnover, we 
analyzed the osteoclast differentiation cycle. To this end, we first checked the number of 
osteoclasts differentiated from the monocytes. This measure showed if PRP or RvEl had the 
potential of suppressing the osteoclasts to form. Figure 3 demonstrates that all doses (5-20%; 
v/v) of PRP resulted in complete inhibition of monocyte-mediated osteoclast formation. 
Likewise, RvEl led to an absolute prevention of osteoclast differentiation from the monocytic 
precursors. 
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Figure 3. Osteoclast formation and PRP or RvEl treatment of monocytes. *p<0.05; 
ANOV A with Bonferroni correction for multiple comparisons. 
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Then, as a function of osteoclast, the activity was tested by the resorptive capacity of the 
osteoclasts. For this purpose, dentin discs were used and analyzed. Figure 4 shows that the 
number of resorptive pits on the discs as a functional characteristic of the osteoclast activity was 
significant! y suppressed by the PRP at all doses tested and R v E 1. 
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Figure 4. Number of resorptive dentin pits in response to PRP or Rvel treatment in 
osteoclasts. *p<0.05; ANOVA with Bonferroni correction for multiple comparisons. 
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Using the dentin pits, then we calculated the area of resorption to measure the horizontal 
distance that the osteoclasts have traveled. Data presented in Figure 5 demonstrates that PRP or 
RvEl treatment not only results in significant reduction of resorptive pits, but also limits the 
resorptive activity of the osteoclasts. 
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Figure 5. Area of resorptive activity of osteoclasts. *p<0.05; ANOVA with Bonferroni 
correction for multiple comparisons. 
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D. Cathepsin K Expression in Osteoclasts 
As a final measure of osteoclastic activity, we have analyzed the cathepsin K expression 
in osteoclasts treated with PRP or RvEl. Figure 6 demonstrates that the RvEl substantially and 
significantly reduces the cathepsin K expression in osteoclasts compared to control while I 0% 
PRP does not significantly inhibit the expression. 
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Figure 6. Cathepsin K expression in osteoclasts. *p<0.05 ; ANOV A with Bonferroni correction 
for multiple comparisons. 
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VI. DISCUSSION 
This study was designed to investigate the impact of PRP and RvEl had on the bone 
turnover kinetics. The hypothesis was derived from recent findings in our laboratory[96] [97] 
where R v E 1 was demonstrated to prevent and reverse the periodontal inflammation resulting in a 
complete regeneration of the alveolar bone in rabbits. The second rationale for developing the 
hypothesis was based on other recent findings from our group where PRP was shown to contain 
several growth factors and significant amounts of lipoxin A4 [ 64]. Therefore, we speculated that 
PRP and RvEl, very distinct molecules could impact the osteoblast and osteoclast activities in 
vitro, which in tum result in restoration of the bone. The results demonstrate that PRP and RvEl 
lead to significant reduction of osteoclast differentiation and activity while substantially 
enhancing the osteoblast function. These findings suggest that the bone healing and regeneration 
could benefit from the delivery of the growth factors necessary for the healing while elimination 
of inflammation would allow the osteoblasts function and utilize these factors. 
Our findings are very close to the findings of Graziani et al. [99],who measured the in 
vitro effect of different PRP concentrations on osteoblasts and fibroblasts. In their study, 
primary human cell cultures were exposed to both activated and non-activated plasma as well as 
various concentrations of PRP (2.5-5.5 x). Cell proliferation was evaluated after 24 and 72 h 
using an MTT proliferation assay. Production of osteocalcin, osteoprotegrin and TGF-~ 1 was 
evaluated after 24 and 72 h. The effect of different PRP concentrations on cell proliferation was 
most notable at 72 h. The maximum effect was achieved with a concentration of2.5 x, with 
higher concentrations resulting in a reduction of cell proliferation. Upregulation of osteocalcin 
levels and downregulation of osteoprotegrin levels were noted with increasing PRP 
concentrations at both 24 and 72 h. TGF-~ 1 levels were stimulated by increasing concentrations 
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of PRP, with the increased levels being maintained at 72 h. In other studies, [100, 101] the 
response of bone marrow stromal cells (BMSCs) to PRP was measured in order to clarify the 
potential role of their combined use in a preclinical phase preceding BMSCs transplantation for 
bone repair and regeneration procedures. The incubation of BMSCs with PRP promoted a 
remarkable, dose- and time- dependent, growth stimulation, that was paralleled to a strong 
increase in the quantity of type I collagen and to a significant decrease in the activity of the early 
osteoblastic differentiation marker, alkaline phosphatase. Once PRP was removed and 
osteogenic inducers were added, alkaline phosphatase returned to levels comparable to the 
control, while the late phenotypic markers, osteocalcin and matrix calcification, were enhanced 
to higher levels than in controls. Their data demonstrated that PRP induces a remarkable ex vivo 
enrichment of BMSCs maintaining their differentiative potential. Thus, PRP represents a valid 
preclinical tool for obtaining an effective, rapid and safe ex vivo expansion ofBMSCs prior to 
their clinical utilization in bone engineering. Another recent study by Kasten et al (2008)[102] 
showed that PRP generates a positive effect on the loading efficiency of mesenchymal stem cells 
on the highly specific surface scaffold calcium-deficient hydroxyapatite (CDHA) that thereby 
reaches the loading efficiency of beta-TCP. PRP improves proliferation, but its osteogenic 
properties on both calcium phosphate scaffolds are weak. Goto et al (2006)[103] also showed 
that PRP induces bone formation via osteoblastic differentiation following subcutaneous 
transplantation. Slapnicka in an in vitro study compared 10%, 25% and 50% concentration of 
PRP on the proliferation of the osteoblasts and found the 10% the most effective stimulant on the 
cell proliferation [104]. They concluded that osteoblasts with 10% activated PRP (0.38x increase 
in platelet count) had the highest viability of all samples containing PRP . Activated PRP 
resulted in higher proliferation of osteoblasts compared with nonactivated PRP at concentrations 
of 10% (0.38x increase in platelet count) and 25% (0.95x increase in platelet count) in culture 
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[ I 04]. The results of Choi et al. (2005) showed that the viability and proliferation of alveolar 
bone cells were suppressed by high PRP concentrations, but were stimulated by low PRP 
concentrations (1-5%). These in vitro results support the view that variations in the PRP 
concentrations might influence the bone formation within the PRP-treated bone grafts. Ogino et 
al (2005) in another in vitro study on osteoblasts stimulated with PRP showed that PRP 
stimulates the proliferation but suppresses the differentiation of rat bone marrow cell (RBMCs ). 
[105]Arpornmaeklong et al. (2004) concluded that PRP showed a dose-dependent stimulation 
effect of cell proliferation, while reducing ALP activity and calcium deposition in the culture. 
[106] 
One of the most valuable data of this study was the comparison of the effect of PRP with 
RvEl in term of stimulation of the osteoblastic activity. The effect ofRvEl on osteoblasts is 
time-dependent and the most level of the osteocalcin in the supematants can be seen after 72 hrs 
of stimulation . There is not that much data available on the literature about the effects of the 
RvEl on osteoblasts. Hasturk et al (2007) found the RvEl as a potent proresolving mediator of 
inflammation derived from omega-3 eicosapentaenoic acid that acts locally to stop leukocyte 
recruitment and promote resolution. [96]RvEl displays potent counter-regulatory and tissue-
protective actions in vitro and in vivo. Promotion of resolution of inflammation as a therapeutic 
target with RvEl resulted in complete restoration of the local lesion. This report was the first to 
show that resolution of inflammation by a naturally occurring endogenous lipid mediator results 
in complete regeneration of pathologically lost tissues, including bone. In this study, when 
osteoblasts were treated with RvEl after 48 and 72 hrs, the osteocalcin levels significantly 
mcreases 
Hirotaka and Kikuchi investigated the efficacy of PRP as an inhibitor of receptor 
activator of NF-kappaB ligand (RANKL)-induced TRAP-positive multinucleated cell formation 
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in RA W264. 7 cells. [ 107]RANKL-induced formation of osteoclasts was significantly inhibited 
by treatment with PRP , while washed platelet treatment was more effective in inhibiting 
osteoclast formation. Their results suggest that PRP and washed platelets are potent inhibitors of 
osteoclast differentiation. These finding are compatible with our results that show PRP can 
decrease the number of mature osteoclasts in the culture. Another study by Ogino et al. (2003) 
showed that PRP suppressed the formation of TRAP-positive osteoclast-like monocytes . 
[ 105]This study suggested that PRP is effective for bone formation by promoting the 
proliferation of osteoblasts and inhibiting the formation of osteoclasts confirming our findings 
about the decreased number of mature osteoclasts in the presence of PRP. 
As shown in Figure 6, cathepsin K expression was reduced but not significantly affected 
by the PRP while the RvEl significantly suppressed the cathepsin K expression in the 
osteoclasts . This is comparable to the previous results that showed the effectiveness ofRvEl to 
inhibit osteoclast activity. Herrera et al (2008) showed that osteoclast differentiation was 
significantly inhibited by RvEl.[98] Peak inhibition was observed at 3 ng/ml ofRvEl-the same 
dose we chose in this study while no significant inhibition was observed at higher doses (30 and 
100 ng/ml). A time-course experiment showed that osteoclast differentiation was inhibited by 
day 4 and day 6 of culture. Similar results were obtained in our study where osteoclast activity 
and differentiation were significantly inhibited by the RvEl. 
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VII. CONCLUSION 
The data presented in this thesis suggest that PRP and RvEl comparably increase the 
osteoblastic activity and suppress the osteoclast differentiation and function. Their effects depend 
on time and concentration. Multiple tools are available to reverse the inflammation and restore 
the lost bone architecture as a result of periodontal disease. 
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